https://www.marketscreener.com/quote/stock/INCYTE-CORPORATION-9675/news/Incyte-Data-from-Phase-3-TRuE-AD-Trials-of-Ruxolitinib-Cream-in-Atopic-Dermatitis-to-be-Presented-30218735/?utm_source=telegram&utm_medium=social&utm_campaign=share